The COVID-19 vaccine boosted the pharmaceutical company Pfizer’s sales up to €2.9 billion ($3.5 billion) in the first quarter. This led to Pfizer racking up its annual expectations for revenue from $15 billion to a whopping $26 billion. Pfizer, who splits the vaccine profits with partner BioNTech, raised full-year revenue up to $72.5 billion from $61.4 billion, mostly due to signed contracts for 1.6 billion vaccine doses in 2021 alone.
Chief Executive Albert Bourla stated that diluted earnings per share hit 86 US cents, with earnings coming from more than 50 countries demanding the vaccine. Bourla expressed his satisfaction with how Pfizer initiated 2021, stating ‘We continued to accelerate production and shipments of our COVID-19 vaccine – many cases exceeding our contractual obligations for delivery timelines.’
#MaltaDaily
Photo Source: BBC